Send this to a friend

Sunovion cleared by FDA to offer depression drug to pediatric patients

Marlborough drugmaker Sunovion has received federal approval for use of a bipolar depression treatment drug in pediatric patients. 
The Food and Drug Administration approval of supplemental new drug application, announced by the company Tuesday, expands the use of the company’s trademark drug Latuda for use in pediatric patients aged 10 to 17 suffering from bipolar depression.
Currently, the drug is ap ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media